Verheilen

Verheilen Therapeutics is a Cambridge-based biotechnology company dedicated to the discovery of small molecule drugs for traditionally undruggable protein targets. The company leverages a proprietary drug discovery platform that combines advanced chemical biology and computational tools to identify novel binding pockets and develop highly selective covalent inhibitors. Currently in the pre-clinical stage, Verheilen's internal pipeline is primarily focused on high-impact targets within oncology and immunology. Led by experienced pharmaceutical executives, including former Pfizer oncology leadership, the firm aims to expand the reach of precision medicine to patients with limited therapeutic options. The company operates with a focus on covalent chemistry to achieve potent and durable inhibition of disease-driving proteins.